NO20043794L - Benzensulfonamidderivater som antipsykotiske midler - Google Patents

Benzensulfonamidderivater som antipsykotiske midler

Info

Publication number
NO20043794L
NO20043794L NO20043794A NO20043794A NO20043794L NO 20043794 L NO20043794 L NO 20043794L NO 20043794 A NO20043794 A NO 20043794A NO 20043794 A NO20043794 A NO 20043794A NO 20043794 L NO20043794 L NO 20043794L
Authority
NO
Norway
Prior art keywords
antipsychotic agents
benzenesulfonamide derivatives
benzenesulfonamide
derivatives
antipsychotic
Prior art date
Application number
NO20043794A
Other languages
English (en)
Inventor
David Gwyn Cooper
Steven Mark Bromidge
Christopher Norbert Johnson
Andrew Derrick Gribble
Andrew Hele Payne
Andrew P Lightfoot
David R Witty
Ian Thomson Forbes
Stephen Frederick Moss
Shahzad Sharooq Rahman
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0203438A external-priority patent/GB0203438D0/en
Priority claimed from GB0203437A external-priority patent/GB0203437D0/en
Priority claimed from GB0204784A external-priority patent/GB0204784D0/en
Priority claimed from GB0204758A external-priority patent/GB0204758D0/en
Priority claimed from GB0212548A external-priority patent/GB0212548D0/en
Priority claimed from GB0219711A external-priority patent/GB0219711D0/en
Priority claimed from GB0224466A external-priority patent/GB0224466D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of NO20043794L publication Critical patent/NO20043794L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Addiction (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Obesity (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20043794A 2002-02-13 2004-09-10 Benzensulfonamidderivater som antipsykotiske midler NO20043794L (no)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
GB0203438A GB0203438D0 (en) 2002-02-13 2002-02-13 Compounds
GB0203437A GB0203437D0 (en) 2002-02-13 2002-02-13 Novel compounds
GB0204784A GB0204784D0 (en) 2002-02-28 2002-02-28 Compounds
GB0204758A GB0204758D0 (en) 2002-02-28 2002-02-28 Novel compounds
GB0212548A GB0212548D0 (en) 2002-05-30 2002-05-30 Novel compounds
GB0219711A GB0219711D0 (en) 2002-08-23 2002-08-23 Novel compounds
GB0224466A GB0224466D0 (en) 2002-10-21 2002-10-21 Compounds
PCT/EP2003/001545 WO2003068752A1 (en) 2002-02-13 2003-02-13 Benzenesulfonamide derivatives as antipsychotic agents

Publications (1)

Publication Number Publication Date
NO20043794L true NO20043794L (no) 2004-09-10

Family

ID=27739513

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20043794A NO20043794L (no) 2002-02-13 2004-09-10 Benzensulfonamidderivater som antipsykotiske midler

Country Status (14)

Country Link
US (1) US20050222124A1 (no)
EP (1) EP1474399A1 (no)
JP (1) JP2005526724A (no)
KR (1) KR20040081201A (no)
CN (1) CN1630642A (no)
AU (1) AU2003215558A1 (no)
BR (1) BR0307557A (no)
CA (1) CA2475783A1 (no)
CO (1) CO5611103A2 (no)
IS (1) IS7388A (no)
MX (1) MXPA04007920A (no)
NO (1) NO20043794L (no)
PL (1) PL371344A1 (no)
WO (1) WO2003068752A1 (no)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050090485A1 (en) * 2002-02-13 2005-04-28 Bromidge Steven M. 7-Arylsulfonamido-2,3,4,5-tetrahydro-1h-benzo'diazepine derivatives with 5ht6 receptor affinity for the reatment of cns disorders
AU2003218660A1 (en) * 2002-02-13 2003-09-04 Glaxo Group Limited Benzenesulfonamide derivatives and their use as dopamine d3 and d2 receptor liga ds
MY133587A (en) 2002-05-29 2007-11-30 Glaxo Group Ltd Aromatic sulfones and their medical use
ES2264003T3 (es) * 2002-10-07 2006-12-16 Glaxo Group Limited Derivados de sulfonamida como agentges antipsicoticos.
GB0321475D0 (en) * 2003-09-12 2003-10-15 Glaxo Group Ltd Novel compounds
GB0327737D0 (en) * 2003-11-28 2003-12-31 Glaxo Group Ltd Novel compounds
GB0327738D0 (en) * 2003-11-28 2003-12-31 Glaxo Group Ltd Novel compound
GB0327741D0 (en) * 2003-11-28 2003-12-31 Glaxo Group Ltd Novel compounds
GB0327740D0 (en) * 2003-11-28 2003-12-31 Glaxo Group Ltd Novel compounds
US20050137186A1 (en) * 2003-12-18 2005-06-23 Abbott Gmbh & Co. Kg. Tetrahydrobenzazepines and their use
WO2005058328A1 (en) * 2003-12-18 2005-06-30 Abbott Gmbh & Co. Kg Tetrahydrobenzazepines and their use in the modulation of the dopamine d3 receptor
TW200611701A (en) * 2004-06-18 2006-04-16 Glaxo Group Ltd Novel compounds
NZ555124A (en) * 2004-10-14 2010-12-24 Abbott Gmbh & Co Kg Arylsulfonylmethyl or Arylsulfonamide substituted aromatic compounds suitable for treating disorders that respond to madulation of the dopamine D3 receptor
FR2878524B1 (fr) * 2004-12-01 2007-01-19 Bioprojet Soc Civ Ile Nouveaux derives d'arylpiperazine
WO2006062481A1 (en) * 2004-12-09 2006-06-15 Biovitrum Ab New benzofuran derivatives and their use in the treatment of obesity, type ii diabetes and cns disorders .
EP1837332A1 (en) * 2006-03-23 2007-09-26 Laboratorios Del Dr. Esteve, S.A. Substituted tetrahydroisoquinoline compounds, their preparation and use in medicaments
EP2314577A1 (en) * 2009-10-16 2011-04-27 Almirall, S.A. Process for manufacturing 2-[(3,5-difluoro-3'-methoxy-1,1'-biphenyl-4-yl)amino]nicotinic acid
CN103145619A (zh) * 2012-06-15 2013-06-12 史慎德 7-氯-6-苯磺酰氨基-2,3,4,5-四氢-1H-苯并[d]氮杂*的制备
RS64027B1 (sr) * 2016-03-22 2023-03-31 Helsinn Healthcare Sa Benzenesulfonil-asimetrične uree i njihove medicinske upotrebe
BR112023005344A2 (pt) * 2020-09-23 2023-05-09 St Jude Childrens Res Hospital Inc Análogos de n-(2-(2,6-dioxopiperidin-3-il)-1,3-dioxoisoindolin- 5-il)arilsulfonamida substituídos como moduladores da proteína cereblon

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DZ2376A1 (fr) * 1996-12-19 2002-12-28 Smithkline Beecham Plc Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
US6316450B1 (en) * 1997-07-11 2001-11-13 Smithkline Beecham P.L.C. Compounds
GB9801392D0 (en) * 1998-01-22 1998-03-18 Smithkline Beecham Plc Novel compounds
GB9803411D0 (en) * 1998-02-18 1998-04-15 Smithkline Beecham Plc Novel compounds
GB9926302D0 (en) * 1999-11-05 2000-01-12 Smithkline Beecham Plc Novel compounds
US20050090485A1 (en) * 2002-02-13 2005-04-28 Bromidge Steven M. 7-Arylsulfonamido-2,3,4,5-tetrahydro-1h-benzo'diazepine derivatives with 5ht6 receptor affinity for the reatment of cns disorders
AU2003218660A1 (en) * 2002-02-13 2003-09-04 Glaxo Group Limited Benzenesulfonamide derivatives and their use as dopamine d3 and d2 receptor liga ds

Also Published As

Publication number Publication date
AU2003215558A1 (en) 2003-09-04
IS7388A (is) 2004-08-06
WO2003068752A1 (en) 2003-08-21
US20050222124A1 (en) 2005-10-06
CN1630642A (zh) 2005-06-22
MXPA04007920A (es) 2004-11-26
PL371344A1 (en) 2005-06-13
JP2005526724A (ja) 2005-09-08
KR20040081201A (ko) 2004-09-20
BR0307557A (pt) 2005-01-04
CO5611103A2 (es) 2006-02-28
CA2475783A1 (en) 2003-08-21
EP1474399A1 (en) 2004-11-10

Similar Documents

Publication Publication Date Title
NO20044654L (no) Piperidinoylpiperidiner som 5-HTIF-agonister
NO20050665L (no) Pyrrolidonderivater som MAOE inhibitoere
NO20044325L (no) 4-anilinokinazolinderivater som antiproliferative midler
NO20043794L (no) Benzensulfonamidderivater som antipsykotiske midler
DK1663996T3 (da) (Thio)carbamoylcyclohexanderivater som D3/D2-receptorantagonister
NO20050426L (no) Arylkarbonylderivater som terapeutiske midler
DK1397364T3 (da) Hidtil ukendte pyrrolderivater som farmaceutiske midler
ATE478870T1 (de) Spiroindolinpiperidinderivate
DK1556385T3 (da) Heterocyclocarboxamid-derivater
ATE450506T1 (de) Indol-3-schwefelderivate
ATE467631T1 (de) Chinuclidinamidderivate
NO20052884D0 (no) Substituerte indolpyridinforbindelser som anti-infeksjonsmidler.
IS7720A (is) Píperidín-N-oxíð-afleiður
ATE438644T1 (de) Chinazolinderivate
DK1578750T3 (da) Kationiske porphyrinderivater som antibakterielle midler
DK2248807T3 (da) N-Phenyl-2-pyrimidinaminderivater
DK1492785T3 (da) 2-hydroxy-3-heteroarylindol-derivater som GSK3-inhibitorer
DK1414803T3 (da) Pyrazolylcarboxanilider som fungicider
NO20051236L (no) Heterobiarylderivater som matriksmetalloproteinaseinhibitorer
NO20033618D0 (no) Ftalayinon-piperidino-derivater som PDE-4-inhibitorer
DK1478629T3 (da) N-aryl-2-oxazolidinon-5-carboxamider og deres derivater og deres anvendelse som antibakterielle midler
DK1442030T3 (da) Thiopen- og thiazolsulfonamider som antineoplastiske midler
DK1828167T3 (da) Acrylamidderivater som antibiotiske midler
NO20044998L (no) Tioksantinderivater som myeloperoksidaseinhibitorer
DK1456206T3 (da) Azaindolylalkylaminderivater som 5-hydroxytryptamin-6-ligander